Hiring trends, layoffs, applicant markets, salary data and what’s working in talent acquisition across life sciences.
Every story from The Talent Take, newest first.
27 companies cut 2,568 people, about 90% fewer than a year ago and the lowest quarter since BioSpace started tracking. New Jersey was hit hardest.
Read the source →Tango is cutting 14%, mostly research staff. EyePoint is halving its workforce, Foghorn is cutting 40%, and GSK plans 1,200+ cuts in Belgium.
Read the source →GSK is putting $800M into biologics production in Pennsylvania, creating 300+ jobs.
Read the source →Biopharma postings have risen for three quarters in a row, and biotech R&D postings were up 42% year on year in June.
Read the source →Applications per job have more than doubled since 2022, while recruiting teams are 55% smaller, according to Greenhouse. AI “apply to everything” tools are a big part of it.
Read the source →R&D is the top target for 49% of biopharma job seekers, followed by technology roles. Hard-to-fill roles are still regulatory, quality, AI/bioinformatics, and commercial leaders with real domain depth.
Read the source →Top-rated employers do; most miss it by a week or more. In a busy market, slow feedback loses your best candidate.
Read the source →Rated on leadership and direction, innovation, research quality and a collaborative, data-driven culture. Scientists choose employers on the science. Show yours.
Read the source →The full archive of The Talent Take.
A three-minute weekly read: funding, launches, leadership moves and what they mean for hiring. Written by QP’s Talent Network. No spam, one-click unsubscribe.
